Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Paxalisib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 136,306Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kazia prunes failed cancer trial data set to form path to FDA
    Kazia prunes failed cancer trial data set to form path to FDA

    11 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-phase-iiiii-clinical-trial-results-for-paxalisib-in-glioblastoma-302193414.html

    PR NEWSWIRE
    11 Jul 2024
    Share Share
    Kazia Announces The Release Of Pnoc022 Clinical Study Abstract
    Kazia Announces The Release Of Pnoc022 Clinical Study Abstract

    15 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-announces-the-release-of-pnoc022-clinical-study-abstract-highlighting-paxalisib-in-diffuse-midline-glioma-patients-ahead-of-the-society-of-neuro-oncology-2023-annual-meeting-301989147.html

    PR NEWSWIRE
    15 Nov 2023
    Share Share
    Kazia Announces Publication In Cancer Therapeutics Highlighting Paxalisib Data
    Kazia Announces Publication In Cancer Therapeutics Highlighting Paxalisib Data

    10 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-announces-publication-in-molecular-cancer-therapeutics-highlighting-paxalisib-preclinical-data-in-melanoma-301984365.html

    PR NEWSWIRE
    10 Nov 2023
    Share Share
    Kazia Provides Preliminary Update From Ongoing Phase 2 Study Of Paxalisib
    Kazia Provides Preliminary Update From Ongoing Phase 2 Study Of Paxalisib

    01 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-provides-preliminary-update-from-ongoing-phase-2-study-of-paxalisib-in-primary-cns-lymphoma-301973774.html

    PR NEWSWIRE
    01 Nov 2023
    Share Share
    PNOC Clinical Study Of Kazia's Paxalisib In Childhood Brain Cancer Expands
    PNOC Clinical Study Of Kazia's Paxalisib In Childhood Brain Cancer Expands

    06 Oct 2022

    // BENZINGA

    https://www.benzinga.com/news/22/10/29166532/pnoc-clinical-study-of-kazias-paxalisib-in-childhood-brain-cancer-expands-internationally

    BENZINGA
    06 Oct 2022
    Share Share
    Kazia Tx Reports Promising Interim Data From Combination Study Of Paxalisib
    Kazia Tx Reports Promising Interim Data From Combination Study Of Paxalisib

    05 Aug 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-promising-interim-data-from-combination-study-of-paxalisib-with-radiotherapy-in-treatment-of-brain-metastases-301600774.html

    PRNEWSWIRE
    05 Aug 2022
    Share Share